Skip to Main Content
Health Metadata Commons
Feedback
Documentation
Login
Home
Search Metadata Commons
Metadata Submission
Resources
Biodiversity Data Sources
Go Back
Project
Metadata Commons Identifier
HMC000047
Required
Project Title
Blood Single-Cell RNA Sequencing of Fibrotic Interstitial Lung Disease Subtypes
Required
Project Description
<p><span style="background-color:rgb(255,255,255);color:rgb(38,38,38);"><span style="-webkit-text-stroke-width:0px;display:inline !important;float:none;font-family:system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;font-size:14px;font-style:normal;font-variant-caps:normal;font-variant-ligatures:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-decoration-color:initial;text-decoration-style:initial;text-decoration-thickness:initial;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;">Interstitial lung diseases (ILDs) are debilitating disorders that cause patients to slowly lose their lung function, resulting in shortness of breath, limited capacity for movement, and subsequent death. Over 4,000 British Columbians currently suffer from some form of ILD, yet not all of them receive proper therapy, partly due to difficulties in identifying the precise ILD subtype.</span></span><br><span style="background-color:rgb(255,255,255);color:rgb(38,38,38);"><span style="-webkit-text-stroke-width:0px;display:inline !important;float:none;font-family:system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;font-size:14px;font-style:normal;font-variant-caps:normal;font-variant-ligatures:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-decoration-color:initial;text-decoration-style:initial;text-decoration-thickness:initial;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;">A correct diagnosis is crucial to administering proper therapy, yet nearly half of ILD patients report a delay in diagnosis of more than one year, which delays optimal disease management and thus increases risk of death.</span><span style="-webkit-text-stroke-width:0px;box-sizing:border-box;font-family:system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;font-size:14px;font-style:normal;font-variant-caps:normal;font-variant-ligatures:normal;font-weight:400;letter-spacing:normal;orphans:2;outline-color:var(--ut-focus-outline-color,-webkit-focus-ring-color);text-align:start;text-decoration-color:initial;text-decoration-style:initial;text-decoration-thickness:initial;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;"> </span><span style="-webkit-text-stroke-width:0px;display:inline !important;float:none;font-family:system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;font-size:14px;font-style:normal;font-variant-caps:normal;font-variant-ligatures:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-decoration-color:initial;text-decoration-style:initial;text-decoration-thickness:initial;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;">Moreover, drug treatment for IPF costs ~$40k/year, whereas other ILD subtypes generally respond well to alternative medications that are ~90% cheaper. It is therefore critical that patients with ILD are diagnosed early and accurately to prompt initiation of effective therapy.</span></span><br><span style="background-color:rgb(255,255,255);color:rgb(38,38,38);"><span style="-webkit-text-stroke-width:0px;display:inline !important;float:none;font-family:system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif;font-size:14px;font-style:normal;font-variant-caps:normal;font-variant-ligatures:normal;font-weight:400;letter-spacing:normal;orphans:2;text-align:start;text-decoration-color:initial;text-decoration-style:initial;text-decoration-thickness:initial;text-indent:0px;text-transform:none;white-space:normal;widows:2;word-spacing:0px;">To address the need for better ILD diagnosis, the goal of this project is to identify diagnostic cellular markers that can accurately distinguish between subtypes of ILD. This will be done by profiling gene expression patterns within individual white blood cells. There is considerable evidence that specific white blood cell populations are important drivers of ILD progression, which may explain prior unsuccessful attempts at identifying ILD subtype-specific markers in whole tissue specimens (i.e. lung, blood) rather than individual cells. Improving diagnosis will result in significant social and economic benefits and improve health outcomes for the thousands of patients suffering from ILDs.</span></span></p>
Project Funder(s)
Genome British Columbia
Project Institution(s)
University of British Columbia
Project Investigator(s)
Christopher Ryerson
,
Scott Tebbutt
Contact Investigator...
Data Access Request URL*
Keywords
interstitial lung disease, single cell sequencing, biomarkers
Publication Link
Study Completed
Cohort
Cohort Name
SCAILD (single-cell analysis of interstitial lung disease)
Required
Study Design
Prospective
Cohort Size
32
Disease/Condition Studied
interstitial lung disease
Enrollment Time Window
2021-2023
Enrollment City
Biobanking Consent Available
Medical History Available
Ethnicity Availability
Time Course
Patient Phenotypes
fibrotic interstitial lung disease
Patient Outcomes
survival
Clinical Data Types Available
demographics, lung function, comorbidities, radiology, antigen reactivity, serology
Time Course Data Points
Groups
Samples and Omics